Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
(OP:
LOBEF
)
0.0400
-0.0007 (-1.72%)
Streaming Delayed Price
Updated: 12:24 PM EDT, Aug 25, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about LOBEF
< Previous
1
2
Next >
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
March 01, 2023
By Richard Dal Monte
Via
TheNewswire.com
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
February 28, 2023
As early as the 1950s, scientists were researching the possible therapeutic benefits of psychedelics such as LSD and psilocybin mushrooms.
Via
Benzinga
Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic
January 27, 2023
Lobe Sciences (OTCQB: LOBEF), the psychedelics company performing drug R&D with sub-hallucinatory doses of psychedelics has signed a research agreement with headache medicine specialist Dr. Lauren R.
Via
Benzinga
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
January 26, 2023
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Mass-Scale Psilocin Clinical Supplies Are Ready For Upcoming Trials
October 14, 2022
Canadian biotech company Lobe Sciences Ltd.
Via
Benzinga
New Share Consolidation of Lobe Sciences Ltd., Here's What Changes
June 08, 2022
Lobe Sciences Ltd.
Via
Benzinga
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
January 26, 2023
Dr. Lauren R. Natbony to be Principal investigator Vancouver, BC – January 26, 2023 — Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) (“Lobe” or the “Company”), a North American Biopharmaceutical company...
Via
FinancialNewsMedia
Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)
January 19, 2023
Via
AB Newswire
Topics
Intellectual Property
Trippy Trading: Top Psychedelic Stocks For 2023
January 17, 2023
When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus,...
Via
TheNewswire.com
Topics
Cannabis
Lobe Sciences Announces Incorporation of Australian Subsidiary
September 23, 2022
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"),...
Via
Newsfile
Lobe Sciences Announces Closing of Private Placement
September 08, 2022
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"),...
Via
Newsfile
Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia
September 01, 2022
Psychedelics biopharma company Lobe Sciences Ltd.
Via
Benzinga
Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
September 01, 2022
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"),...
Via
Newsfile
Topics
Cannabis
This Psychedelic Company Just Signed An Exclusive Deal For Psilocin Clinical Trials In Australia
August 10, 2022
Life sciences company Lobe Sciences Ltd.
Via
Benzinga
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
July 19, 2022
Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications.
Via
Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
June 15, 2022
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.
Via
Benzinga
Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) Featured in Coverage of Planet MicroCap’s Virtual Investor Conference
April 19, 2022
Via
Investor Brand Network
Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event
March 07, 2022
Via
Investor Brand Network
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.